Only in Titles

Search results for: Anti human Antithrombin

paperclip

#33802928   2021/03/17 To Up

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.

Blood platelets' adenosine receptors (AR) are considered to be a new target for the anti-platelet therapy. This idea is based on in vitro studies which show that signaling mediated by these receptors leads to a decreased platelet response to activating stimuli. In vivo evidence for the antithrombotic activity of AR agonists published to date were limited, however, to the usage of relatively high doses given in bolus. The present study was aimed at verifying if these substances used in lower doses in combination with inhibitors of P2Y could serve as components of dual anti-platelet therapy. We have found that a selective A agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine (HE-NECA) improved the anti-thrombotic properties of either cangrelor or prasugrel in the model of ferric chloride-induced experimental thrombosis in mice. Importantly, HE-NECA was effective not only when applied in bolus as other AR agonists in the up-to-date published studies, but also when given chronically. In vitro thrombus formation under flow conditions revealed that HE-NECA enhanced the ability of P2Y inhibitors to decrease fibrinogen content in thrombi, possibly resulting in their lower stability. Adenosine receptor agonists possess a certain hypotensive effect and an ability to increase the blood-brain barrier permeability. Therefore, the effects of anti-thrombotic doses of HE-NECA on blood pressure and the blood-brain barrier permeability in mice were tested. HE-NECA applied in bolus caused a significant hypotension in mice, but the effect was much lower when the substance was given in doses corresponding to that obtained by chronic administration. At the same time, no significant effect of HE-NECA was observed on the blood-brain barrier. We conclude that chronic administration of the A agonist can be considered a potential component of a dual antithrombotic therapy. However, due to the hypotensive effect of the substances, dosage and administration must be elaborated to minimize the side-effects. The total number of animals used in the experiments was 146.
Dawid Polak, Marcin Talar, Nina Wolska, Dagmara W Wojkowska, Kamil Karolczak, Karol Kramkowski, Tomasz A Bonda, Cezary Watala, Tomasz Przygodzki

1429 related Products with: Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.

100ug100 μg100ug Lyophilized100ug100 μg100 μg100ug Lyophilized100ug Lyophilized100 μg100ug

Related Pathways

paperclip

#33761699   // To Up

Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.

Dual anti-platelet therapy (DAPT) with aspirin and clopidogrel has been the mainstay of treatment for patients with acute coronary syndrome (ACS). However, the recurrence of thrombotic events, potential aspirin and clopidogrel hypo-responsiveness, and other limitations of DAPT have led to the development of newer oral anti-thrombotic drugs. Apixaban, a new non-vitamin K antagonist, has been approved for use. In this meta-analysis, we aimed to compare the bleeding outcomes observed with the addition of apixaban to DAPT for the treatment of patients with ACS.
Jing Jin, Xiaojun Zhuo, Mou Xiao, Zhiming Jiang, Linlin Chen, Yashvina Devi Shamloll

1437 related Products with: Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.

100.00 ul1 ml100.00 ul0.1 mg100.00 ul100.00 ul

Related Pathways

paperclip

#33756546   2021/03/22 To Up

Coagulation Factors Accumulate During Normothermic Liver Machine Perfusion Regardless of Donor Type and Severity of Ischemic Injury.

Coagulation factors may inform on liver function during normothermic machine perfusion (NMP). We investigated whether graft ischemic injury impairs the accumulation of (anti)coagulation factors during NMP of porcine and human livers.
Nicholas Gilbo, Marc Jacquemin, David Nasralla, Silvia Lazzaro, Louis Libbrecht, Renaud Lavend'homme, Kathelijne Peerlinck, Rutger J Ploeg, Peter J Friend, Jacques Pirenne, Diethard Monbaliu, Ina Jochmans

1746 related Products with: Coagulation Factors Accumulate During Normothermic Liver Machine Perfusion Regardless of Donor Type and Severity of Ischemic Injury.

0.1mg96T0.1 mg0.25mg 5 G100ug200ul

Related Pathways

paperclip

#33652345   2021/02/27 To Up

Serum Albumin, Body Mass Index, and Preceding Xa and P2Y12 Inhibitors Predict Prognosis of Recurrent Ischemic Stroke.

A third to half of recurrent stroke occur while on antiplatelet therapy, but no study has explored factors relating to prognosis of recurrent ischemic stroke. This study aimed to clarify the risk factors to determine the clinical outcome of recurrent ischemic stroke.
Ryusei Kiboshi, Sousuke Satoh, Kasumi Mikami, Maiko Kitajima, Mayumi Urushizaka, Norifumi Metoki, Tomohiro Osanai

2726 related Products with: Serum Albumin, Body Mass Index, and Preceding Xa and P2Y12 Inhibitors Predict Prognosis of Recurrent Ischemic Stroke.

96T200ul100 mg50mg10 mg50ul10gm100 ul1000 tests100 μg50 mg

Related Pathways

paperclip

#33591368   2021/02/01 To Up

Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage.

Although the use of factor Xa (FXa) inhibitors has increased substantially over the past decade, there are limited data on characteristics and outcomes of FXa inhibitor-associated intracerebral hemorrhage (ICH).
Ying Xian, Shuaiqi Zhang, Taku Inohara, Maria Grau-Sepulveda, Roland A Matsouaka, Eric D Peterson, Jonathan P Piccini, Eric E Smith, Kevin N Sheth, Deepak L Bhatt, Gregg C Fonarow, Lee H Schwamm

2745 related Products with: Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage.

10 mg

Related Pathways

paperclip

#33529924   2021/01/30 To Up

Sex Differences in Management and Outcomes of Cardioembolic Stroke: Post HOC Analyses of the RELAXED Study.

Experimental models have clearly demonstrated sex differences in the pathophysiology of stroke and prognosis, however clinical evidence remains elusive. In this study, we examined sex differences as a post hoc analysis of RELAXED (Recurrent Embolism Lessened by rivaroxaban, an anti-X agent, of Early Dosing for acute IS and TIA with atrial fibrillation) Study.
Takashi Okada, Kazutaka Uchida, Fumihiro Sakakibara, Hiroto Kageyama, Masahiro Yasaka, Kazunori Toyoda, Etsuro Mori, Teruyuki Hirano, Toshimitsu Hamasaki, Hiroshi Yamagami, Takehiko Nagao, Shinichiro Uchiyama, Kazuo Minematsu, Shinichi Yoshimura,

2229 related Products with: Sex Differences in Management and Outcomes of Cardioembolic Stroke: Post HOC Analyses of the RELAXED Study.

5 G11 Set100 μg

Related Pathways

    No related Items
paperclip

#33483034   2020/12/15 To Up

A regular fucan sulfate from Stichopus herrmanni and its peroxide depolymerization: Structure and anticoagulant activity.

Marine sulfated polysaccharides have aroused widespread concern for their various structures and bioactivities. Peroxide depolymerization is a common strategy in analysis of structures and structure-activity relationships of polysaccharides. However, confirming the depolymerization process and exact structures of the degradation products is still a considerable challenge. This study reported the structures of a fucan sulfate (FS) from sea cucumber Stichopus herrmanni and its depolymerized products (dFS) prepared by peroxide degradation. The FS was elucidated with a highly regular structure, {-3)-L-Fuc-(α1-}. Structure analysis of oligosaccharides purified from dFS suggested that peroxide degradation involved in cleavage of glycosidic bonds and oxidative modification of reducing end of sugar residue, while no break in sugar ring was observed. Both FS and series of dFSs exhibited significant anticoagulant activities due to their anti-thrombin effects in presence of heparin cofactor II and their potencies were related to their molecular sizes, dFS with ∼ 20 kDa showed the strongest activity.
Xiaomei Li, Shanni Li, Jie Liu, Lisha Lin, Huifang Sun, Wenjiao Yang, Ying Cai, Na Gao, Lutan Zhou, Hongbo Qin, Ronghua Yin, Jinhua Zhao

2811 related Products with: A regular fucan sulfate from Stichopus herrmanni and its peroxide depolymerization: Structure and anticoagulant activity.

100ug1,000 tests100ug1000 1 mg1000 tests100ul100 mg100ul10 mg500 MG

Related Pathways

paperclip

#33472803   2021/01/20 To Up

Internal jugular vein thrombosis associated with .

, which occurs as part of the oral microflora, is an uncommon cause of infection. However, it can cause serious bloodstream infections including infective endocarditis. Although oral bacteria, most commonly the spp, can cause internal jugular vein (IJV) thrombophlebitis, there are no reported cases of IJV thrombosis caused Here we report a patient with septic IJV thrombosis with bacteraemia. A middle-aged man presented to our hospital with fever and altered mental status. Blood cultures were positive for , and pan-scan CT with contrast showed left IJV thrombosis, pulmonary embolism and abscesses in the gluteal muscles. The patient was successfully treated with antibiotics. When confronted with bacteraemia in patients with poor oral hygiene, it is necessary to be cautious of the fact that this organism can cause IJV thrombophlebitis.
Honami Kawai, Toshiaki Shiojiri

1563 related Products with: Internal jugular vein thrombosis associated with .

100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg200ul

Related Pathways

paperclip

#33441484   // To Up

The 3--sulfation of heparan sulfate modulates protein binding and lyase degradation.

Humans express seven heparan sulfate (HS) 3--sulfotransferases that differ in substrate specificity and tissue expression. Although genetic studies have indicated that 3--sulfated HS modulates many biological processes, ligand requirements for proteins engaging with HS modified by 3--sulfate (3-OS) have been difficult to determine. In particular, the context in which the 3-OS group needs to be presented for binding is largely unknown. We describe herein a modular synthetic approach that can provide structurally diverse HS oligosaccharides with and without 3-OS. The methodology was employed to prepare 27 hexasaccharides that were printed as a glycan microarray to examine ligand requirements of a wide range of HS-binding proteins. The binding selectivity of antithrombin-III (AT-III) compared well with anti-Factor Xa activity supporting robustness of the array technology. Many of the other examined HS-binding proteins required an IdoA2S-GlcNS3S6S sequon for binding but exhibited variable dependence for the 2-OS and 6-OS moieties, and a GlcA or IdoA2S residue neighboring the central GlcNS3S. The HS oligosaccharides were also examined as inhibitors of cell entry by herpes simplex virus type 1, which, surprisingly, showed a lack of dependence of 3-OS, indicating that, instead of glycoprotein D (gD), they competitively bind to gB and gC. The compounds were also used to examine substrate specificities of heparin lyases, which are enzymes used for depolymerization of HS/heparin for sequence determination and production of therapeutic heparins. It was found that cleavage by lyase II is influenced by 3-OS, while digestion by lyase I is only affected by 2-OS. Lyase III exhibited sensitivity to both 3-OS and 2-OS.
Pradeep Chopra, Apoorva Joshi, Jiandong Wu, Weigang Lu, Tejabhiram Yadavalli, Margreet A Wolfert, Deepak Shukla, Joseph Zaia, Geert-Jan Boons

1058 related Products with: The 3--sulfation of heparan sulfate modulates protein binding and lyase degradation.

1000 TESTS/0.65ml200 100ug Lyophilized 100ul250ul96T100ug Lyophilized200 100ul1 mg 100ul100.00 ug

Related Pathways

paperclip

#33435162   2021/01/10 To Up

Bioactive Lipids of Marine Microalga sp. SABC 012504 with Anti-Inflammatory and Anti-Thrombotic Activities.

Microalgae are at the start of the food chain, and many are known producers of a significant amount of lipids with essential fatty acids. However, the bioactivity of microalgal lipids for anti-inflammatory and antithrombotic activities have rarely been investigated. Therefore, for a sustainable source of the above bioactive lipids, the present study was undertaken. The total lipids of microalga sp., isolated from the Irish coast, were fractionated into neutral-, glyco-, and phospho-lipids, and were tested in vitro for their anti-inflammatory and antithrombotic activities. All tested lipid fractions showed strong anti-platelet-activating factor (PAF) and antithrombin activities in human platelets (half maximal inhibitory concentration (IC) values ranging ~25-200 μg of lipid) with the highest activities in glyco- and phospho-lipid fractions. The structural analysis of the bioactive lipid fraction-2 revealed the presence of specific sulfoquinovosyl diacylglycerols (SQDG) bioactive molecules and the HexCer-t36:2 (t18:1/18:1 and 18:2/18:0) cerebrosides with a phytosphingosine (4-hydrosphinganine) base, while fraction-3 contained bioactive phosphatidylcholine (PC) and phosphatidylethanolamine (PE) molecules. These novel bioactive lipids of sp. with putative health benefits may indicate that marine microalgae can be a sustainable alternative source for bioactive lipids production for food supplements and nutraceutical applications. However, further studies are required towards the commercial technology pathways development and biosafety analysis for the use of the microalga.
Katie Shiels, Alexandros Tsoupras, Ronan Lordan, Constantina Nasopoulou, Ioannis Zabetakis, Patrick Murray, Sushanta Kumar Saha

1391 related Products with: Bioactive Lipids of Marine Microalga sp. SABC 012504 with Anti-Inflammatory and Anti-Thrombotic Activities.

100ul0.1 mg100ul1 ml200 1000 TESTS/0.65ml100.00 ul 10 UG1000 409 μg100ug100ug

Related Pathways